Literature DB >> 3925488

Methylphenidate: rate-dependent drug effects in hyperactive boys.

K Weber.   

Abstract

The purpose of this study was to test whether the effects of methylphenidate on rates of operant responding in hyperactive boys differed depending on the predrug baseline rates of responding. On the basis of the rate dependency hypothesis, dose-related decreases from high baseline rates and increases from low baseline rates would be predicted. A multiple FR-DRL (fixed ratio-differential reinforcement of low Rates) schedule was used to generate high and low rates of responding on a simple operant task, using nickels as reinforcers. Three dosage levels were used: placebo, 0.3 mg/kg, and 1.0 mg/kg of methylphenidate. Both experimenter and subject were blind to dosage level. Surprisingly, DRL response rates were not significantly affected by the drug, while FR rates increased linearly with increasing dose. Thus, the predicted between-schedule differences were not found. However, within the FR schedule, changes from baseline to postdrug rates within each active drug condition were consistent with the rate dependency hypothesis; i.e., subjects with lower baselines increased their response rates, while subjects with higher baselines decreased or did not change their rates. The opposite effect occurred following placebo.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3925488     DOI: 10.1007/bf00428421

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  23 in total

Review 1.  Rate-dependent effects of drugs: a review of the literature.

Authors:  D J Sanger; D E Blackman
Journal:  Pharmacol Biochem Behav       Date:  1976-01       Impact factor: 3.533

2.  Evidence from rats that morphine tolerance is a learned response.

Authors:  S Siegel
Journal:  J Comp Physiol Psychol       Date:  1975-07

3.  Analysis of effects of psychopharmacological agents in behavioral terms.

Authors:  P B DEWS
Journal:  Fed Proc       Date:  1958-12

4.  Studies on behavior. II. The effects of pentobarbital, methamphetamine and scopolamine on performances in pigeons involving discriminations.

Authors:  P B DEWS
Journal:  J Pharmacol Exp Ther       Date:  1955-12       Impact factor: 4.030

5.  Morphine analgesic tolerance: its situation specificity supports a Pavlovian conditioning model.

Authors:  S Siegel
Journal:  Science       Date:  1976-07-23       Impact factor: 47.728

6.  Effects of d-amphetamine and secobarbital on key press rates in normal humans.

Authors:  M Stitzer; E F Domino
Journal:  Arch Int Pharmacodyn Ther       Date:  1974-02

7.  Methylphenidate and the activity of hyperactives in the informal setting.

Authors:  M J Ellis; P A Witt; R Reynolds; R L Sprague
Journal:  Child Dev       Date:  1974-03

8.  Methylphenidate and thioridazine: learning, reaction time, activity, and classroom behavior in disturbed children.

Authors:  R L Sprague; K R Barnes; J S Werry
Journal:  Am J Orthopsychiatry       Date:  1970-07

9.  The role of predrug signals in morphine analgesic tolerance: support for a Pavlovian conditioning model of tolerance.

Authors:  S Siegel; R E Hinson; M D Krank
Journal:  J Exp Psychol Anim Behav Process       Date:  1978-04

10.  Effects of d-amphetamine and diazepam on fixed-interval, fixed-ratio responding in humans.

Authors:  P A Tewes; M W Fischman
Journal:  J Pharmacol Exp Ther       Date:  1982-05       Impact factor: 4.030

View more
  2 in total

Review 1.  Animal models to guide clinical drug development in ADHD: lost in translation?

Authors:  Jeffery R Wickens; Brian I Hyland; Gail Tripp
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

2.  Methylphenidate decreased the amount of glucose needed by the brain to perform a cognitive task.

Authors:  Nora D Volkow; Joanna S Fowler; Gene-Jack Wang; Frank Telang; Jean Logan; Christopher Wong; Jim Ma; Kith Pradhan; Helene Benveniste; James M Swanson
Journal:  PLoS One       Date:  2008-04-16       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.